What is the appropriate treatment for agitation and aggression in patients with dementia?

Treatment for Agitation and Aggression in Dementia

Begin with nonpharmacological interventions first, and reserve antipsychotic medications only for severe, dangerous symptoms or significant patient distress after behavioral strategies have been attempted. 1

Stepwise Treatment Algorithm

Step 1: Comprehensive Assessment (Required Before Any Treatment)

You must systematically evaluate 1:

• Type, frequency, severity, pattern, and timing of agitation/aggression
• Pain assessment - untreated pain is a common, modifiable trigger 2
• Medical contributors: UTI, dehydration, constipation, medication side effects
• Environmental triggers: overstimulation, understimulation, safety hazards
• Caregiver factors: communication style, unrealistic expectations, caregiver stress
• Sensory impairments: hearing loss, vision problems

Step 2: Nonpharmacological Interventions (First-Line Treatment)

Implement behavioral and environmental strategies before considering medications 1, 2:

Immediate actions:

• Treat underlying medical problems (pain, infection, dehydration)
• Discontinue medications that may worsen behavior
• Optimize treatment of pre-existing psychiatric conditions
• Address sensory impairments (glasses, hearing aids)

Environmental modifications:

• Reduce overstimulation or increase stimulation as needed
• Establish predictable routines
• Ensure adequate lighting and way-finding cues
• Remove dangerous objects (knives, guns)
• Install safety equipment (grab bars, bath mats)

Caregiver education:

• Teach that behaviors are symptoms of dementia, not intentional
• Train in simplified communication techniques
• Adjust expectations to match patient's current abilities
• Provide caregiver support and stress management

Step 3: Pharmacological Treatment (Only When Necessary)

Antipsychotics should ONLY be used when 1:

• Symptoms are severe, dangerous, or cause significant patient distress
• Nonpharmacological interventions have been tried and documented
• Risk/benefit discussion completed with patient (if feasible) and surrogate decision maker

When Antipsychotics Are Indicated:

Preferred agents based on 2026 evidence:

• Brexpiprazole: strongest evidence and most favorable safety profile 3
• Risperidone: effective but requires monitoring for cerebrovascular and extrapyramidal risks 3, 4, 5
• Aripiprazole: effective with similar monitoring needs 3

Prescribing principles 1:

• Start at low dose
• Titrate to minimum effective dose as tolerated
• Assess response with quantitative measures 1
• If no response after 4 weeks at adequate dose → taper and discontinue 1
• If significant side effects occur → reassess risk/benefit and consider discontinuation 1

Alternative Pharmacological Options:

When safety is the priority 3:

• Citalopram: consider for agitation in Alzheimer's disease 4, 6
  • Monitor for QT prolongation 6
• Agomelatine: safer alternative 3

Cognitive enhancers (if not already prescribed):

• Cholinesterase inhibitors or memantine: moderate efficacy for general behavioral symptoms 4, 6
• Should be initiated regardless to enhance cognition 6

Adjunctive treatments:

• Trazodone: for insomnia or sundowning 6

Limited efficacy (reserve for refractory cases):

• Anticonvulsants 3

Step 4: Ongoing Monitoring and Reassessment

For patients responding to antipsychotics 1:

• Regularly reassess need for continued treatment
• Discuss tapering with patient/surrogate and family
• Review initial goals, observed benefits, side effects, and risks of continued exposure
• Do not use long-term or routinely - evidence does not support this 3

Critical Pitfalls to Avoid

1. Never start antipsychotics without attempting nonpharmacological interventions first (except in emergency situations with imminent danger) 1, 5

2. Never continue antipsychotics indefinitely - reassess regularly and taper when appropriate 1, 3

3. Never ignore treatable medical causes - pain, infection, and medication side effects are frequently overlooked 2

4. Never underestimate caregiver contribution - poor communication and unrealistic expectations often perpetuate behaviors 2

5. Black box warning awareness: Antipsychotics increase mortality risk in elderly patients with dementia - this must be part of informed consent 1, 5

Evidence Quality Note

The 2016 APA guidelines 1 provide the authoritative framework, with 2026 research 3 offering the most current evidence on specific agent selection, particularly highlighting brexpiprazole's superior profile. The European Academy of Neurology 5 and multidisciplinary expert panel 2 reinforce the primacy of nonpharmacological approaches and systematic assessment.